Topics
Sector
Geography
Subject

Videos Library

All Videos

1457
videos of thought-leading presentations and interactive panel discussions from life science industry visionaries and experts

The NextLevel LifeSciences Videos Library is the full collection of video recordings (and supporting documentation) from all NextLevel LifeSciences events.

Latest Videos

Presentation

Evaluating critical methodological issues to optimally address the research question: What are the trade-offs among study designs

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Real-World Evidence & Late-Phase Research, Global (non-specific)
Availability: FREE

Research questions around real-world evidence development can include a breadth of evidence needs including the prevalence, clinical characteristics, treatment patterns and effect, etc. of a given cohort and/or sub-cohort. Addressing the question(s) can be complicated by the size/characteristics of the cohort and the complexities of the health system. Consequently, we propose a practical and feasible approach to assessing study design options which we believe will meet both the research objectives as well as consider the realities of timelines and budget constraints. We will discuss a number of options for study design and cohort identification, including use of administrative claims and/or electronic healthcare records, sitebased recruitment, and web-survey panelists. We will identify a set of common methodological challenges and discuss the relative strengths of each approach in addressing these issues.

Speaker

Teresa K Wilcox
Scientific Director, Real World Evidence, Evidera, USA

Presentation

Breaking the classical barriers to collaboration and scientific discovery: Distance and data size

Related topics: Pharmaceutical/Biotech, Discovery & R&D Innovation, Global (non-specific)
Availability: FREE

Life sciences organisations need to dramatically reduce analytics time and speed up clinical interventions, but most still rely on shipping physical disks due to inherent problems with existing networks and transfer protocol inefficiencies. Spending days to transport data is not a viable option, this session will explore technology infrastructure for file transfer that will catalyse the transition from 1GbE to 10GbE and beyond.

  • Enabling geographically distributed collaborative teams to exchange huge data sets at maximum speed, regardless of distance and network conditions.
  • Utilising proven, secure and reliable transfer technology, widely adopted for business-critical data movement.
  • Transferring large data sets, including next-generation genomic sequencing sets, amounting to hundreds of gigabytes.
Speaker

Per Hansen
Regional Manager Sales Engineering EMEA, Aspera (an IBM Company),UK

Presentation

From Big Data to precision medicine: Trends, challenges & opportunities

Related topics: Pharmaceutical/Biotech, Diagnostics, Clinical, IT & Big Data, Discovery & R&D Innovation, Global (non-specific)
Availability: FREE
Speaker

Thomas Wilckens
Chief Executive Officer, CSO & Founder, InnVentis, Germany

Presentation

Six key buyer trends reshaping MedTech selling & pricing

Related topics: MedTech, Europe, Market Access & HEOR, Commercial
Availability: FREE

The MedTech industry is at an inflection point. Healthcare providers at every level are professionalising their procurement and creating tectonic shifts in their demands on your pricing, sales, and tendering and contracting operations. While the industry appears to be aware of these shifts and what the impacts will be, many MedTech companies are struggling to identify and prioritise the changes they need to make to stay ahead of these trends without sacrificing revenue or growth.

Speaker

Peter Zimmermann
Director Customer Success Europe
Model N, Switzerland

Presentation

Developing a commercial model based on value

Related topics: MedTech, Europe, Market Access & HEOR, Commercial
Availability: FREE
  • Early stage or product launch: When is the right moment to focus on value?
  • Identifying the key value propositions to drive the market.
  • Building the relevant economic data to support value claims.
  • Case example: From feature-centric to value-based model
Speaker

Ernesto M. Nogueira
Managing Director
ValueConnected, Netherlands

Presentation

Leveraging support programmes to enhance medical communications

Related topics: Pharmaceutical/Biotech, Europe, Medical Affairs & Stakeholder Engagement
Availability: FREE
  • How pharma can utilise digital programmes to support publication strategy.
  • Using materials and real world evidence to reach new KOL audiences.
Speaker

Ian Smyth
Director
MEDNET Consult

Presentation

The changing face of KOL partnerships

Related topics: Pharmaceutical/Biotech, Europe, Medical Affairs & Stakeholder Engagement
Availability: FREE
  • Compliance and transparency regulations are causing many pharmaceutical companies to re-evaluate how they pay and partner with external experts.
  • How do we define a KOL and what are models for effective KOL engagement in the changing environment?
Speaker

Rob Barker
CEO, Succinct Medical Communications, UK

Presentation

Real world data strategy and programs of research: A roadmap for late phase success

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Real-World Evidence & Late-Phase Research, Global (non-specific)
Availability: FREE
  • In the context of spending constraints, and aggressive go-tomarket timelines, the generation of compelling real world evidence of the effectiveness, safety and value of a novel therapy or medical device has never been more challenging.
  • Peri- and post-approval evidence requirements, which vary markedly across countries, are increasingly demanding both in terms of data needs, and total research and development cost.
  • To navigate this reality, a comprehensive evidence development plan that systematically identifies gaps, and organises and prioritises a synergistic program of scientifically robust real world studies in support of market access is of paramount importance.
  • An evidence development plan that is based on a thoughtful and stepwise multi-national data and feasibility assessment strategy, will result in the right evidence to support a product’s value proposition while optimising cost savings and timeline efficiencies.
  • Data strategy and feasibility assessment case studies alongside a roadmap for cost and timeline savings in the context of technology enabled programs of research will be presented.
Speakers

Krista A. Payne
Vice President, Late Phase Studies, Real World Evidence
Evidera, Canada

Dimitra Lambrelli
Research Evidence, Real World Evidence
Evidera, UK

Presentation

Wiring medical affairs capabilities into the organisational DNA

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Global (non-specific)
Availability: FREE
  • Why linking medical affairs strategy and capability together is important.
  • How to build capabilities in medical affairs functions at different stages of their growth.
  • Future challenges in building medical affairs capability.
  • Sharing case study examples.
Speaker

Sophie Hall
Head of Capability Building Practice
Pope Woodhead, UK

Presentation

Medical affairs organisational models: A market-driven approach

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Global (non-specific)
Availability: FREE
  • Assessing the market through a medical affairs lens.
  • How market specific characteristics influence medical affairs capabilities.
  • How the market dictates medical affairs size and structure.
  • How specific roles within medical affairs vary due to market characteristics.
Speaker

Suma Ramadas
Managing Director, Medical Affairs
Campbell Alliance, USA

Presentation

Global review of innovative pricing arrangements: Shifting dynamics and new considerations

Related topics: Pharmaceutical/Biotech, Europe, Market Access & HEOR
Availability: FREE
  • Payer perception/considerations of innovative pricing in the context of health budget pressures.
  • Analytics overview of geographies and therapeutic areas where key changes are occurring.
  • Key strategic lessons over how these agreements are being designed.
Speaker

Gustav Ando
Vice President of Life Sciences
IHS

Presentation

Understand the real drivers of HTA decision-making in oncology: What clinical and economic factors influence positive vs negative recommendations?

Related topics: Pharmaceutical/Biotech, Europe, Market Access & HEOR, Oncology
Availability: FREE
  • How do payers evaluate products in an increasingly crowded marketplace.
  • How successful are companies in getting new products approved?
  • Comparing major payers: Where are similarities and where are the difference in their evaluations?
  • Do companion diagnostics make a difference in the approval success rate?
Speaker

Anke van Engen
Principal, Advisory Services, Quintiles, Netherlands

Presentation

Is your market access organization ready for the evolving access challenges in Latin America?: A primer on organizational development to reflect marketplace changes.

Related topics: Pharmaceutical/Biotech, Market Access & HEOR, Latin America
Availability: FREE
Speakers

Miguel Martin de Bustamante
Associate, CBPartners

Sandeep Duttagupta
Vice President, CBPartners

Presentation

Navigating post-marketing requirements worldwide: What to anticipate as you move towards submission

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Real-World Evidence & Late-Phase Research, Asia Pacific
Availability: FREE
  • Review of post-marketing requirements in the USA, Europe, and South Korea.
  • How to interpret the demand of the authorities,
  • Proactive planning to drive design.
  • Real-world case studies from the USA, Europe and South Korea.
Speaker

Alexandre Malouvier
Director of Scientific Affairs, Late Phase Services,
PRA Health Sciences

Presentation

Practical strategies for implementing RWE studies in Asia Pacific

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Real-World Evidence & Late-Phase Research, Asia Pacific
Availability: FREE
  • Differences between real-world evidence studies and randomized controlled trials.
  • Asia Pacific country specific examples of real-world evidence studies.
  • Local regulations on study approval and execution.
  • KOL value and working with investigators in APAC.
Speakers

William Maier
Chief Scientific Officer, Mapi Group, UK

Isabelle Grau
Director, Real World Evidence APAC, Mapi Group, Australia

Presentation

Biosimilar, but different: Establishing (or defending) value through multi-criteria decision analytic (MCDA) modelling

Related topics: Pharmaceutical/Biotech, Europe, Market Access & HEOR, Biosimilars
Availability: FREE
  • How the complex characteristics of biologics (and biosimilars) contribute to perceived value to different stakeholders.
  • The salient issues facing upstarts (marketers of biosimilars) and defenders (marketers of “original” biologics) in communicating comparative worth to stakeholders.
  • How MCDA modelling methods can assist both groups in better defining and communicating value.
Speaker

Mason W. Russell
MAPE, Vice President
Truven Health Analytics, USA

Presentation

Cell & gene therapies: A global perspective of HTA, funding & reimbursement challenges

Related topics: Pharmaceutical/Biotech, Market Access & HEOR, Global (non-specific)
Availability: FREE
  • Overview of cell & gene therapies.
  • Health technology assessment & cost effectiveness challenges.
  • Who pays? Healthcare system determinants of funding / reimbursement.
  • Affordability: Pricing and budget impact challenges.
  • Lessons learned: Early case studies.
Speaker

Neil Palmer
President & Principal Consultant
PDCI Market Access Inc.

Presentation

Leveraging RWE to support market access: Lessons learned

Related topics: Pharmaceutical/Biotech, Europe, Market Access & HEOR, Real-World Evidence & Late-Phase Research
Availability: FREE

Market access is value contextual, thus using RWE to secure appropriate market access allows evidence to reflect effectiveness in the real world where protocols may not be followed, patients don’t take their medications, and where every population is viewed as unique requiring data to reflect that specific population . This presentation walks through the reality of developing RWE for an EUmarketed, post-anaesthesia medication using a retrospective observational study format and demonstrates the importance of thinking carefully about your strategy (the benefits, risks, costs and mitigations) before embarking.

Speaker

Mervyn D. Hall
Director of Market Access – Europe
Truven Health Analytics, UK

Presentation

Live events in the digital age: Case Study of a catalyst for building integrated and sustained engagement with healthcare professionals

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Global (non-specific), Digital & Technology
Availability: FREE
  • The problem: High investment with limited reach and high output that is short-lived.
  • The objective: Capitalising on events to extend the value through sustained targeted engagement.
  • The strategy: An end-to-end programme designed to be multicontent, multi-event & multi-channel.
  • The evidence: Research and metrics that supports this approach and better outcomes.
Speaker

Tiberio Catania
Commercial Director
EPG Health Media, UK

Presentation

Breaking the “fail-cycle” of KOL CRM Solutions

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Global (non-specific), Digital & Technology
Availability: FREE

A plethora of studies suggest that an astonishing 50 – 75% of all CRM implementations fail in some form. So we started our KOL CRM development programme with the assumption “why should ours be any different?” Our two-year case study highlights the many challenges we (vendor & our clients) encountered in the medical affairs context, our many failings, and the innovations we built to overcome them. We’ll also present a simple framework for Medical Affairs to help maximise the success of CRM implementations to boost external expert management.

Speaker

Sanjay Singhvi
Director, System Analytic, UK

Presentation

Case study review: Leveraging technology to enhance KOL & stakeholder engagement

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Global (non-specific), Digital & Technology
Availability: FREE
  • Assessment of viable online solutions to KOL stakeholder engagement in the pharmaceutical industry.
  • Review major pharmaceutical company cases using web-based engagement solutions.
  • Understand a variety of KOL engagement scenarios, shared learnings and best organisation practices for success.
Speaker

Peter Gannon
SVP Business Partnerships, Within3, Inc.

Presentation

Fit-for-purpose process and technology to support observational research

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Real-World Evidence & Late-Phase Research, Global (non-specific)
Availability: FREE
Speaker

Jane Turner
Executive Director of Late Phase Research, INC Research, UK

Presentation

Successfully integrating EHR and EDC data

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Real-World Evidence & Late-Phase Research, Clinical, IT & Big Data, Global (non-specific)
Availability: FREE
  • How companies can successfully navigate the EHR and secondarydata landscape.
  • Designing and implement studies that reap the benefits of combining EDC and EHR data to answer key questions.
  • Transforming the theory of real-world hybrid studies into reality.
Speaker

Angela Vinken
Sr. Director Observational Research
Parexel, Netherlands

Presentation

Hybrid studies: Combining different data sources to answer clinical and economic research needs

Related topics: Pharmaceutical/Biotech, Market Access & HEOR, Medical Affairs & Stakeholder Engagement, Real-World Evidence & Late-Phase Research, Global (non-specific)
Availability: FREE
  • Real-world data sources: What information needs can they address?
  • Considerations, potential challenges and solutions.
  • Types of hybrid studies with case studies.
  • Chart reviews with additional data collection from patients.
  • Recruitment of patients from registries for burden of disease outcomes.
  • Linkage of different types of registries with the addition of patient interviews.
Speakers

William C. Maier
Chief Scientific Officer, Mapi Group, UK

Jennifer Eriksson
Associate Director, Real World Strategy & Analytics
Mapi Group, Sweden

Presentation

Compassionate use programs as a strategy for market access

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Global (non-specific), Patient-Centricity & Care
Availability: FREE
  • Why and when to run them?
  • Benefits and pitfalls.
  • Strategic considerations.
  • Case study: The French ATU programme.
Speaker

Alexandre Malouvier
Director of Scientific Affairs, Late Phase Services
PRA Health Sciences

Presentation

How digital medical communications can support a global medical affairs strategy: Opportunities and compliance considerations

Related topics: Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Global (non-specific)
Availability: FREE
Speakers

Rob Barker
CEO, Succinct Medical Communications, UK

James Turnbull
Digital Technical Director, Succinct Medical Communications, UK

Presentation

Market access challenges and opportunities for clinical applications of Next Generation Sequencing (NGS)

Related topics: MedTech, Diagnostics, Europe, Market Access & HEOR
Availability: FREE
  • Review of benefits of NGS and challenges associated with securing payment for multiplex testing technologies.
  • Overview of EU5 payment systems for diagnostics.
  • Case studies: Payment for NGS oncology applications in Germany and France.
  • Case studies: Reimbursement initiatives for non-invasive, prenatal testing.
  • Best practices/insights for innovators.
Speaker

Charles Mathews
Vice President
Boston Healthcare, USA

Presentation

Translating hospitals’ needs into actual value stories

Related topics: MedTech, Europe, Market Access & HEOR
Availability: FREE
  • Identifying decision-makers’ needs.
  • Assessing the relevant data to support claims.
  • Building a concrete value story.
  • Next steps: Teams, not tools, demonstrate value.
Speaker

Ernesto M. Nogueira
Managing Director
ValueConnected, Netherlands

Presentation

Understanding The Changes in European Market Access in Medical Devices

Related topics: MedTech, Europe, Market Access & HEOR
Availability: FREE
Speaker

Mattias Kyhlstedt
CEO
Synergus AB, Sweden

Register to view both free videos and browse premium content (and event documentation).

1457
videos of thought-leading presentations and interactive panel discussions from life science industry visionaries and experts
300+
new videos added every year!